Interleukin-6 levels in female rats with protamine sulfate-induced chronic cystitis treated with hyaluronic acid

International Journal of Urology

Volumn 20, Issue 10, 2013, Pages 1017-1022

  Lv, Yi Song ^a,b   Yao, You Sheng ^a   Lin, Ming En ^a,c   Rong, Lu ^a   Deng, Bi Hua ^a   Huang, Jian ^a   Hao, Wei Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Bladder pain syndrome; Hyaluronic acid; Interleukin 6; Interstitial cystitis; Protamine sulfate

Indexed keywords

HYALURONIC ACID; INTERLEUKIN 6; MESSENGER RNA; PROTAMINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CAPACITY; CHRONIC DISEASE; CONTROLLED STUDY; CYSTITIS; CYSTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MICTURITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

BLADDER PAIN SYNDROME; HYALURONIC ACID; INTERLEUKIN-6; INTERSTITIAL CYSTITIS; PROTAMINE SULFATE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANIMALS; CYSTITIS, INTERSTITIAL; DISEASE MODELS, ANIMAL; DRUG MONITORING; FEMALE; HEPARIN ANTAGONISTS; HYALURONIC ACID; INTERLEUKIN-6; PROTAMINES; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; URINARY BLADDER; URINATION;

EID: 84884974865     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12090     Document Type: Article

References (27)

1. Hanno P, Lin A, Nordling J etal. Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol. Urodyn. 2010; 29: 191-198.
2. Wein AJ, Hanno PM. Targets for therapy of the painful bladder. Urology 2002; 59: 68-73.
3. van de Merwe JP, Nordling J, Bouchelouche P etal. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol. 2008; 53: 60-67.
4. Grover S, Srivastava A, Lee R, Tewari AK, Te AE. Role of inflammation in bladder function and interstitial cystitis. Ther. Adv. Urol. 2011; 3: 19-33.
5. Westropp JL, Buffington CA. In vivo models of interstitial cystitis. J. Urol. 2002; 167: 694-702.
6. Chuang YC, Chancellor MB, Seki S etal. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivity. Urology 2003; 61: 664-670.
7. Soler R, Bruschini H, Freire MP, Alves MT, Srougi M, Ortiz V. Urine is necessary to provoke bladder inflammation in protamine sulfate induced urothelial injury. J. Urol. 2008; 180: 1527-1531.
8. Bassi PF, Costantini E, Foley S, Palea S. Glycosaminoglycan Therapy for bladder diseases: emerging new treatments. Eur. Urol. Suppl. 2011; 10: 451-459.
9. Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2011; 22: 401-405.
10. Lv YS, Zhou HL, Mao HP, Gao R, Wang YD, Xue XY. Intravesical hyaluronic acid and alkalinized lidocaine for the treatment of severe painful bladder syndrome/interstitial cystitis. Int. Urogynecol. J. 2012; 23: 1715-1720.
11. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res. Ther. 2006; 8 (Suppl 2): S3.
12. Erickson DR, Xie SX, Bhavanandan VP etal. A comparison of multiple urine markers for interstitial cystitis. J. Urol. 2002; 167: 2461-2469.
13. Lamale LM, Lutgendorf SK, Zimmerman MB, Kreder KJ. Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology 2006; 68: 702-706.
14. Sairanen J, Hotakainen K, Tammela TL, Stenman UH, Ruutu M. Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. Urology 2008; 71: 630-633.
15. Daha LK, Lazar D, Simak R, Pflüger H. Is there a relation between urinary interleukin-6 levels and symptoms before and after intra-vesical glycosaminoglycan substitution therapy in patients with bladder pain syndrome/interstitial cystitis? Int. Urogynecol. J. Pelvic Floor Dysfunct. 2007; 18: 1449-1452.
16. Ho DR, Chen CS, Lin WY, Chang PJ, Huang YC. Effect of hyaluronic acid on urine nerve growth factor in cyclophosphamide-induced cystitis. Int. J. Urol. 2011; 18: 525-531.
17. Andersson KE, Soler R, Füllhase C. Rodent models for urodynamic investigation. Neurourol. Urodyn. 2011; 30: 636-646.
18. Pehrson R, Stenman E, Andersson KE. Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur. Urol. 2003; 44: 495-499.
19. Giannantoni A, Bini V, Dmochowski R etal. Contemporary management of the painful bladder: a systematic review. Eur. Urol. 2012; 61: 29-53.
20. Kushner L, Moldwin RM. Efficiency of questionnaires used to screen for interstitial cystitis. J. Urol. 2006; 176: 587-592.
21. Humphrey L, Arbuckle R, Moldwin R etal. The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur. Urol. 2012; 61: 271-279.
22. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003; 24: 25-29.
23. Han JH, Lee MY, Myung SC. The effect of endothelin-1 on the production of interleukin-6 in cultured human detrusor smooth muscle cells, and the effect of interleukin-6 on the contractile response of bladder smooth muscle strips from rats. BJU Int. 2009; 104: 707-712.
24. Weng TI, Wu HY, Lin PY, Liu SH. Uropathogenic Escherichia coli-induced inflammation alters mouse urinary bladder contraction via an interleukin-6-activated inducible nitric oxide synthase-related pathway. Infect. Immun. 2009; 77: 3312-3319.
25. Peters KM, Diokno AC, Steinert BW. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guérin treat interstitial cystitis by altering the immune profile in the bladder? Urology 1999; 54: 450-453.
26. Boucher WS, Letourneau R, Huang M etal. Intravesical sodium hyaluronate inhibits the rat urinary mast cell mediator increase triggered by acute immobilization stress. J. Urol. 2002; 167: 380-384.
27. Starkman JS, Martinez-Ferrer M, Iturregui JM, Uwamariya C, Dmochowski RR, Bhowmick NA. Nicotinic signaling ameliorates acute bladder inflammation induced by protamine sulfate or cyclophosphamide. J. Urol. 2008; 179: 2440-2446.